FCCC LOGO Faculty Publications
Chun SG , Simone CB 2nd , Amini A , Chetty IJ , Donington J , Edelman MJ , Higgins KA , Kestin LL , Movsas B , Rodrigues GB , Rosenzweig KE , Slotman BJ , Rybkin II , Wolf A , Chang JY
American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020
J Thorac Oncol. 2021 Jan;16(1) :66-75
Back to previous list
Abstract
INTRODUCTION: Combined modality therapy with concurrent chemotherapy and radiation has long been the standard of care for limited-stage SCLC (LS-SCLC). However, there is controversy over best combined modality practices for LS-SCLC. To address these controversies, the American Radium Society (ARS) Thoracic Appropriate Use Criteria (AUC) Committee have developed updated consensus guidelines for the treatment of LS-SCLC. METHODS: The ARS AUC are evidence-based guidelines for specific clinical conditions that are reviewed by a multidisciplinary expert panel. The guidelines include a review and analysis of current evidence with application of consensus methodology (modified Delphi) to rate the appropriateness of treatments recommended by the panel for LS-SCLC. Agreement or consensus was defined as less than or equal to 3 rating points from the panel median. The consensus ratings and recommendations were then vetted by the ARS Executive Committee and subject to public comment before finalization. RESULTS: The ARS Thoracic AUC committee developed multiple consensus recommendations for LS-SCLC. There was strong consensus that patients with unresectable LS-SCLC should receive concurrent chemotherapy with radiation delivered either once or twice daily. For medically inoperable T1-T2N0 LS-SCLC, either concurrent chemoradiation or stereotactic body radiation followed by adjuvant chemotherapy is a reasonable treatment option. The panel continues to recommend whole-brain prophylactic cranial irradiation after response to chemoradiation for LS-SCLC. There was panel agreement that prophylactic cranial irradiation with hippocampal avoidance and programmed cell death protein-1/programmed death-ligand 1-directed immune therapy should not be routinely administered outside the context of clinical trials at this time. CONCLUSIONS: The ARS Thoracic AUC Committee provide consensus recommendations for LS-SCLC that aim to provide a groundwork for multidisciplinary care and clinical trials.
Notes
1556-1380 Chun, Stephen G Simone, Charles B 2nd Amini, Arya Chetty, Indrin J Donington, Jessica Edelman, Martin J Higgins, Kristin A Kestin, Larry L Movsas, Benjamin Rodrigues, George B Rosenzweig, Kenneth E Slotman, Ben J Rybkin, Igor I Wolf, Andrea Chang, Joe Y Journal Article United States J Thorac Oncol. 2021 Jan;16(1):66-75. doi: 10.1016/j.jtho.2020.10.020. Epub 2020 Nov 6.